BCDA - BioCardia, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.0700
-0.0800 (-1.93%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.1500
Open4.1300
Bid3.8000 x 800
Ask4.0600 x 900
Day's Range3.8000 - 4.1300
52 Week Range3.1500 - 20.7900
Volume3,849
Avg. Volume32,952
Market Cap28M
Beta (5Y Monthly)2.99
PE Ratio (TTM)N/A
EPS (TTM)-2.9560
Earnings DateMay 20, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.33
  • GlobeNewswire

    BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights

    SAN CARLOS, Calif., Nov. 19, 2019 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.

  • Investors Who Bought BioCardia (NASDAQ:BCDA) Shares A Year Ago Are Now Down 80%
    Simply Wall St.

    Investors Who Bought BioCardia (NASDAQ:BCDA) Shares A Year Ago Are Now Down 80%

    BioCardia, Inc. (NASDAQ:BCDA) shareholders should be happy to see the share price up 21% in the last month. But that...

  • GlobeNewswire

    BioCardia to Present at Dawson James Securities 5th Annual Small Cap Growth Conference

    SAN CARLOS, Calif., Oct. 28, 2019 -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.

  • GlobeNewswire

    BioCardia Receives CE Mark Renewal For Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter Through May 2024

    SAN CARLOS, Calif., Oct. 08, 2019 -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced.

  • GlobeNewswire

    BioCardia Announces the Appointment of Two New Board Members

    BioCardia (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the appointment of experienced CEOs Jim Allen and Andrew Blank to its Board of Directors, effective October 1, 2019. Mr. Allen is Chief Executive Officer and President of Sea Star, Inc., a real estate development company, and has served in that capacity since he founded the company in February 1989. Six of his ventures have resulted in sales to publicly-traded companies.

  • GlobeNewswire

    BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures

    SAN CARLOS, Calif., Oct. 01, 2019 -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced.

  • GlobeNewswire

    BioCardia Announces Positive DSMB Recommendation to Continue Phase 3 Pivotal CardiAMP Heart Failure Study as Planned

    The ongoing multi-center, double-blinded, randomized (3:2), sham-controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide. Secondary efficacy endpoints include quality of life as measured by the Minnesota Heart Failure Quality of Life self-assessment, and superiority relative to MACE and survival.

  • GlobeNewswire

    BioCardia Reports 2019 Second Quarter Financial Results and Business Highlights

    SAN CARLOS, Calif., Aug. 21, 2019 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.

  • GlobeNewswire

    BioCardia Announces Issuance of European Patent for Breakthrough Diagnostic Assay for Patient Selection Prior to Cardiac Cell Therapy Delivery

    Today, autologous cardiac cell therapy – where a patient’s own cells are used – is challenged by patient variation, which makes outcomes unpredictable, and by the high costs associated with manufacturing single-batch therapy remotely for each patient. BioCardia’s new patent addresses a potential solution to these problems – a diagnostic approach for patient selection that identifies a specific biomarker signature in a patient’s bone marrow. This test enables a physician to determine if a patient is a good candidate for either of the Company’s two lead clinical indications of heart failure or chronic myocardial ischemia prior to treatment, allowing for point-of-care processing of the therapy and eliminating the significant expense of selecting and processing cells remotely.

  • GlobeNewswire

    BioCardia Announces Closing of $10.0 Million Public Offering

    BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the closing of its previously announced public offering of 1,666,667 units at a price to the public of $6.00 per unit.  Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $6.30 per share.  The common stock and warrants were immediately separable from the units and were issued separately. The common stock and warrants began trading on the Nasdaq Capital Market on August 2, 2019, under the symbols “BCDA” and “BCDAW,” respectively.

  • GlobeNewswire

    BioCardia Announces Pricing of $10.0 Million Public Offering and Uplisting to Nasdaq

    BioCardia, Inc. (NasdaqCM: BCDA, BCDAW), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offering of 1,666,667 units at a price to the public of $6.00 per unit. Each unit issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $6.30 per share. The common stock and warrants will be immediately separable from the units and will be issued separately.

  • GlobeNewswire

    BioCardia Signs Exclusive Development Agreement With AstraZeneca

    BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it has signed an extension to a 2017 development agreement with AstraZeneca [NYSE:AZN] for BioCardia’s Helix™ biotherapeutic delivery catheter system. Under the terms of the initial pre-clinical phase of the relationship, BioCardia will receive a sizable upfront payment, a portion of which will be creditable to BioCardia biotherapeutic delivery systems, support and training. The agreement is exclusive with respect to a class of biotherapeutic agents that BioCardia is not currently developing on its own or with any other party and is time limited.

  • GlobeNewswire

    BioCardia Announces Issuance of Chinese Patent for Image-Guided Biotherapeutic Delivery

    BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the China National Intellectual Property Administration has recently issued the Company Patent No: ZL 2014 8 00125575 for “Target Site Selection, Entry and Update with Automatic Image Annotation,” with a term to January 7, 2034. The patent describes the use of software that merges images from magnetic resonance imaging (MRI) or computed tomography (CT) with fluoroscopic imaging to plan, document and deliver cell, gene, protein and other therapies using interventional catheter systems. The Company has patents pending for image-guided technology in the U.S., Europe and Japan.

  • GlobeNewswire

    BioCardia Announces Reverse Stock Split and Plan for Listing on a Major Stock Exchange

    BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that a reverse stock split of its common stock, $0.001 par value, at a ratio of one-for-nine, is effective today, June 6, 2019.  The Company’s common stock will begin trading on a split adjusted basis when the markets open under the new trading symbol (BCDAD) and in 20 business days, the trading symbol will revert back to our existing symbol, “BCDA”.  The Company’s common stock has been assigned a new CUSIP number of 09060U507 in connection with the reverse stock split. As a result of the reverse split, each nine pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 43.6 million shares to approximately 4.8 million shares.  The reverse stock split will also apply to common stock issuable upon the exercise of the Company’s outstanding stock options and warrants for common stock.  There is no change to the number of authorized shares under the Company’s Certificate of Incorporation, as amended.  The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable.  The reverse stock split will not affect the par value of the common stock.

  • GlobeNewswire

    Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia’s Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class

    BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive results from a study of the company’s Helix™ Biotherapeutic Delivery System for cell therapy used to treat patients early following acute myocardial infarction (AMI) to prevent long term heart failure.

  • GlobeNewswire

    BioCardia Reports 2019 First Quarter Financial Results and Business Highlights

    SAN CARLOS, Calif., May 20, 2019 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.

  • GlobeNewswire

    BioCardia Receives FDA Clearance for AVANCE Steerable Introducer for Transseptal Access to Heart

    SAN CARLOS, Calif., May 08, 2019 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.

  • Business Wire

    BioCardia Reports 2018 Financial Results and Recent Business Highlights

    BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018, filed its annual 10-K with the Securities and Exchange Commission, and shared recent business highlights.

  • GlobeNewswire

    Predictive Technology Group Names Jay M. Moyes to Its Board of Directors

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. “We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group.